Existence of an immunoglobulin G component of naturally occurring HLA class I antibodies that are not directed against self‐antigens in human serum

Zhou, Biao; Saito, Satoshi; Nakazawa, Yozo; Kobayashi, N.; Matsuda, Masayuki; Matsumoto, Yorihiko; Hosoyama, T.; Koike, Kenichi

doi:10.1111/j.1399-0039.2008.01074.x

Cited by 15 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The progress made so far on the discovery of natural HLA Abs in humans projects that, in the future, a greater number and incidence of natural allo-HLA IgG Abs will be recorded in healthy nonalloimmunized males. A number of investigators provided different explanations for the presence of natural HLA Abs (7,11,12,43). Some contended that they are the result of a polyclonal, continuous immune response against exogenous Ags (5, 6, 8-12).…”

Section: Discussionmentioning

confidence: 99%

Antibodies to HLA-E in Nonalloimmunized Males: Pattern of HLA-Ia Reactivity of Anti–HLA-E–Positive Sera

Ravindranath

Kaneku

El‐Awar

et al. 2010

The Journal of Immunology

View full text Add to dashboard Cite

Natural anti-HLA Abs found in sera of healthy nonalloimmunized males recognize HLA-Ia alleles parallel to those recognized by anti–HLA-E mAbs (MEM-E/02/06/07). Therefore, some of the HLA-Ia Abs seen in healthy males could be due to anti–HLA-E Abs cross-reacting with HLA-Ia. If anti–HLA-E Abs occur in healthy nonalloimmunized males, it can be assessed whether they evoke HLA-Ia reactivity as do mouse HLA-E mAbs. IgG and IgM Abs to HLA-E and HLA-Ia alleles are identified in sera of healthy males using microbeads coated with recombinant denatured HLA-E or a panel of rHLA-Ia alleles. The pattern of allelic recognition is comparable to that of anti–HLA-E mAbs. Sixty-six percent of the sera with HLA-E IgG have a high level of HLA-Ia IgG, whereas 70% of those with no anti–HLA-E Abs have no HLA-Ia Abs. HLA-E IgM/IgG ratios of sera are divided into four groups: IgMLow/IgGLow, IgMHigh/IgGLow, IgMHigh/IgGHigh, and IgMLow/IgGHigh. These groups correspond to anti–HLA-Ia IgM/IgG ratio groups. When HLA-E IgM and IgG are absent or present in males, the IgM or IgG of HLA-Ia are similarly absent or present. The mean fluorescent intensity of HLA-Ia Abs correlates with that of anti–HLA-E Abs. Most importantly, HLA-E and HLA-Ia reactivities of the sera are inhibited by the shared, but cryptic, peptide sequences 117AYDGKDY123 and 137DTAAQIS143. Therefore, Abs to the H chain of HLA-E may be responsible for some of the HLA-Ia allele reactivity of the natural HLA-Ia Ab in human sera. Absence of any anti–HLA-Ia Abs in 112 nonvegans and the presence of the same in vegans suggest that dietary meat proteins might not have induced the natural allo-HLA Abs.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibodies to HLA-E in Nonalloimmunized Males: Pattern of HLA-Ia Reactivity of Anti–HLA-E–Positive Sera

Ravindranath

Kaneku

El‐Awar

et al. 2010

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Consequently, it may contain HLA antibodies because several allo-HLA antibodies are known to occur naturally in the sera of both men (nonalloimmunized) and women. [9][10][11][12][13] MoralesBuenrostro et al 11 demonstrated the specificities and incidence of these allo-HLA-I Abs in nonalloimmunized males. Neither the origin nor cause of anti-HLA Abs occurring in healthy individuals has been established.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic preparations of IVIg contain naturally occurring anti–HLA-E antibodies that react with HLA-Ia (HLA-A/-B/-Cw) alleles

Ravindranath

Terasaki

Pham

et al. 2013

Blood

View full text Add to dashboard Cite

show abstract

“…We adopted a highly sensitive FlowPRA method to survey the amount of PRA. 10) Positive PRA was defined as ≥ 10% of PRA class I or class II. Variables evaluated: Perioperative parameters, including donor and recipient characteristics, were obtained.…”

Section: Methodsmentioning

confidence: 99%

Late Rejection Occurred in Recipients Who Experienced Acute Cellular Rejection Within the First Year After Heart Transplantation

et al. 2015

View full text Add to dashboard Cite

SummarySerial endomyocardial biopsies (EMBs) are scheduled even several years after heart transplantation (HTx) to monitor for late rejection (LR). However, repeated EMBs are associated with an increased risk for fatal complications and decrease the quality of life of the recipient. We retrospectively analyzed clinical data from 42 adult recipients who had received HTx and were followed > 1 year at the University of Tokyo Hospital. Five recipients experienced LR at 1130 ± 157 days after HTx, and all 5 had experienced acute cellular rejection (ACR) with ISHLT grade ≥ 2R within the first year, which was treated with methylprednisolone pulse therapy (sensitivity, 1.000; specificity, 0.7027). Logistic regression analyses demonstrated that positive panel reactive antibody (PRA) was the only significant predictor for LR among all parameters at 1 year after HTx (P = 0.020, odds ratio 24.00). Among the 5 recipients with LR, LR occurred earlier in the two PRA positive recipients than in those with a negative PRA (981 ± 12 versus 1230 ± 110 days, P = 0.042). Among the perioperative parameters, gender mismatch [n = 13 (31%)] was the only significant predictor for ACR within the first year in logistic regression analyses (P = 0.042, odds ratio 4.200). In conclusion, the current schedule of serial EMBs should perhaps be reconsidered for recipients without any history of ACR within the first year due to their lower risk of LR. (Int Heart J 2015; 56: 174-179)

show abstract

Existence of an immunoglobulin G component of naturally occurring HLA class I antibodies that are not directed against self‐antigens in human serum

Cited by 15 publications

References 26 publications

Antibodies to HLA-E in Nonalloimmunized Males: Pattern of HLA-Ia Reactivity of Anti–HLA-E–Positive Sera

Antibodies to HLA-E in Nonalloimmunized Males: Pattern of HLA-Ia Reactivity of Anti–HLA-E–Positive Sera

Therapeutic preparations of IVIg contain naturally occurring anti–HLA-E antibodies that react with HLA-Ia (HLA-A/-B/-Cw) alleles

Late Rejection Occurred in Recipients Who Experienced Acute Cellular Rejection Within the First Year After Heart Transplantation

Contact Info

Product

Resources

About